Drug intelligence / Profile preview

bromhexine + spironolactone

Development stage: Unknown
Lead developer: Lomonosov Moscow State University Medical Research and Educational Center
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of bromhexine, a mucolytic and anticough drug that inhibits transmembrane serine protease 2 (TMPRSS2), and spironolactone, an aldosterone receptor antagonist with antiandrogenic effects. This combination has been studied for treating COVID-19, with research suggesting it may be effective by inhibiting virus entry into cells and reducing inflammation and fibrosis.

Targets

AR (Adrenergic receptors)MR (Mineralocorticoid receptor)TMPRSS2 (Transmembrane protease serine 2)

Beyond the preview

Go deeper on bromhexine + spironolactone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bromhexine + spironolactone.

Explore the full profile